Indoco Remedies Ltd

The approval allows the company to market a generic version of Briviact 10 mg/mL oral solution, the reference listed drug (RLD) of UCB, Inc. The company said its Brivaracetam Oral Solution has been determined to be bioequivalent and therapeutically equivalent to the RLD. The product will be manufactured at Indoco Remedies' facility located at L-14, Verna Industrial Area, Verna, Goa ' 403722, India. Brivaracetam Oral Solution (10 mg/mL) is a prescription antiepileptic drug indicated for the treatment of partial-onset seizures in patients aged one month and older. Aditi Panandikar, managing director (MD) said, 'The ANDA approval for Brivaracetam is a significant milestone for us as we continue to strengthen our presence in the Regulated Markets. We are committed to offering innovative and affordable healthcare to patients worldwide.' Indoco Remedies is engaged in the manufacturing and marketing of Formulations and Active Pharmaceutical Ingredients. The Company caters to both Domestic and International markets. The company's consolidated net loss of Rs 23.64 crore in Q3 FY26 as against net loss of Rs 27.30 crore in Q3 FY25. Revenue from operations rose 7.9% year on year to Rs 434.34 crore in Q3 FY26. Powered by Capital Market - Live

Net Loss of Indoco Remedies reported to Rs 29.79 crore in the quarter ended December 2025 as against net loss of Rs 26.39 crore during the previous quarter ended December 2024. Sales rose 7.92% to Rs 434.34 crore in the quarter ended December 2025 as against Rs 402.45 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales434.34402.45 8 OPM %7.252.99 - PBDT6.85-3.23 LP PBT-25.16-31.95 21 NP-29.79-26.39 -13 Powered by Capital Market - Live

Indoco Remedies has allotted 55,700 equity shares under ESOP on 03 February 2026. Consequent to this allotment, the paid up equity share capital has increased to Rs. 18,46,07,210 (consisting of 9,23,03,605 equity shares of face value of Rs. 2 each). Powered by Capital Market - Live

Indoco Remedies announced final approval of the Company's Abbreviated New Drug Application (ANDA) for Lacosamide Oral Solution USP, 10 mg/mL, to market, a generic equivalent to the reference listed drug (RLD), Vimpat Oral Solution, 10 mg/mL, of UCB, Inc. (UCB), from USFDA. Lacosamide Oral Solution USP, 10 mg/mL, is bioequivalent and therapeutically equivalent to the reference listed drug, Vimpat Oral Solution, 10 mg/mL, of UCB, Inc. (UCB). Lacosamide Oral Solution USP, will be manufactured by Indoco Remedies, at their manufacturing facility located at L-14, Verna Industrial Area, Verna, Goa - 403722 in India. Lacosamide Oral solution is used to treat partial onset seizures and primary generalized tonic-clonic seizures in adults and children with epilepsy who are at least 4 years old.Powered by Capital Market - Live

Indoco Remedies will hold a meeting of the Board of Directors of the Company on 3 February 2026.Powered by Capital Market - Live

Revenue from operations stood at Rs 471.83 crore in the second quarter of FY26, up 9.59% as against Rs 430.66 crore posted in Q2 FY25. The company reported a pre-tax loss of Rs 13.35 crore in Q2 FY26, compared with a pre-tax loss of Rs 4.84 crore in Q2 FY25. The firm also recorded exceptional items amounting to Rs 0.53 crore during the quarter. EBITDA for the quarter stood at Rs 53.4 crore, compared with Rs 52.9 crore in the corresponding quarter of the previous year. Aditi Panandikar, MD, Indoco Remedies, said, 'International formulation and API businesses had a good growth this quarter. The India formulation business performance was impacted due to revision in the GST rates. We are confident of regaining momentum in the coming quarters. Indoco is a fully integrated, research-oriented pharmaceutical company with a strong global presence. The Company's turnover is US$ 180 million with a human capital of over 6000 employees, including over 400 skilled scientists and field staff who are the strength of the organization. Shares of Indoco Remedies fell 1.72% to currently trade at Rs 268.50 on the BSE. Powered by Capital Market - Live

Net Loss of Indoco Remedies reported to Rs 7.93 crore in the quarter ended September 2025 as against net loss of Rs 9.57 crore during the previous quarter ended September 2024. Sales rose 9.56% to Rs 471.83 crore in the quarter ended September 2025 as against Rs 430.66 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales471.83430.66 10 OPM %9.129.35 - PBDT19.2523.98 -20 PBT-13.00-4.84 -169 NP-7.93-9.57 17 Powered by Capital Market - Live

Indoco Remedies will hold a meeting of the Board of Directors of the Company on 6 November 2025.Powered by Capital Market - Live

Indoco Remedies has entered into a Sale Agreement and Lease Agreement on 29 August 2025 for sale and lease back of part of the Company's movable properties at its Waluj Facility located at B-19 MIDC, Waluj, Aurangabad, Maharashtra - 431136 (Waluj Facility) and AnaCipher Clinical Research Organisation located at 2nd, 3rd & 4th Floor, Mirrakamshetty Mall, Opp. Doordarshan Bhavan, Ramanthapur Medchal-Malkajgiri District, Hyderabad - 500013, Telangana (CRO) on the terms and conditions as mentioned therein. The sale of the aforesaid movable properties will not have any impact on the manufacturing or business of the Company, as the Company will continue to use the said movable properties on lease basis. Powered by Capital Market - Live

Indoco Remedies announced that the Annual General Meeting(AGM) of the company will be held on 11 September 2025.Powered by Capital Market - Live